Cost-effectiveness of maternal immunisation by Abrysvo® or a single injection of a monoclonal antibody (Beyfortus®) in infants for infant protection against infection by the respiratory syncytial virus in Belgium (Study 2024-51)
Record ID 32018013774
English
Authors' objectives:
Infections by the Respiratory Syncytial Virus (RSV) can cause serious lower respiratory tract (lung) disease and are a major source of disease burden in young children during their first years of life. Infants are particularly at risk of severe RSV infection. Two new products recently arrived on the Belgian market to prevent RSV disease by passive immunisation: a maternal vaccine (Abrysvo®) given between 32 and 36 weeks of pregnancy to prevent RSV in babies from birth through 6 months of age; and a monoclonal antibody (nirsevimab, Beyfortus®) to be injected in infants of unvaccinated mothers once before the RSV season starts, or at birth for infants born during the RSV season. This KCE study will assess the risk-benefit balance of these two products, as well as the expected cost-effectiveness of Belgian programmes using them. The results are expected by June 2025.
Details
Project Status:
Ongoing
Anticipated Publish Date:
2025
English language abstract:
An English language summary is available
Publication Type:
Rapid Review
Country:
Belgium
MeSH Terms
- Cost-Effectiveness Analysis
- Antibodies, Monoclonal
- Respiratory Syncytial Virus Vaccines
- Respiratory Syncytial Virus Infections
- Infant
- Vaccination
- Pregnancy
- Pregnant Women
- Respiratory Syncytial Virus, Human
- Immunity, Maternally-Acquired
Keywords
- Respiratory Syncytial Virus Vaccines
- Antibodies Monoclonal
- Cost-Effectiveness Analysis
Contact
Organisation Name:
Belgian Health Care Knowledge Centre
Contact Address:
Administrative Centre Botanique, Doorbuilding (10th floor), Boulevard du Jardin Botanique 55, B-1000 Brussels, Belgium tel: +32 2 287 33 88 fax: +32 2 287 33 85
Contact Name:
info@kce.fgov.be
Contact Email:
info@kce.fgov.be
Copyright:
<p>Belgian Health Care Knowledge Centre (KCE)</p>
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.